Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Basement membrane

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Basement membrane. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-002391-14 Sponsor Protocol Number: SAWV1003 Start Date*: 2005-09-29
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: Pulsed Intravenous Methylprednisolone for Ocular Pemphigoid- A Pilot Study
    Medical condition: ocular mucous membrane pemphigoid
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004082-39 Sponsor Protocol Number: GOOD-IDES-01 Start Date*: 2017-01-23
    Sponsor Name:Linköping University
    Full Title: An Open-Label Phase II Study in anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES
    Medical condition: Anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10063039 Anti-GBM antibody LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002069-21 Sponsor Protocol Number: D5180C00013 Start Date*: 2018-10-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults with Inadequately Controlled Asthma on Inhaled C...
    Medical condition: Severe Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000485-36 Sponsor Protocol Number: G0500705 Start Date*: 2006-08-23
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Trust
    Full Title: A randomised, double blind, placebo controlled study to Assess The Effect of Antibiotic Therapy on Chronic Rejection in Human Lung Transplantation
    Medical condition: Post Lung Transplantation Chronic Rejection identified as bronchiolitis obliterans syndrome (BOS)
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-006664-29 Sponsor Protocol Number: cro955 Start Date*: 2008-02-26
    Sponsor Name:Imperial College
    Full Title: The effect of inhaled corticosteroids (ICS) on airway smooth muscle in asthma
    Medical condition: Asthma is a disease characterised by reversible airways obstruction, bronchial hyper-responsiveness (BHR), and chronic inflammation of the bronchial mucosal lining. Structural changes in the airwa...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003884-12 Sponsor Protocol Number: EXTRAStudy Start Date*: 2015-12-22
    Sponsor Name:AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII
    Full Title: A pilot, prospective, randomized, open-label, blinded endpoint (PROBE) histopathology trial to assess the effects of ACE- inhibition therapy on glomerular proliferative lesions in patients with ext...
    Medical condition: Extracapillary glomerulonephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10018376 Glomerulonephritis proliferative PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005987-67 Sponsor Protocol Number: AK802 Start Date*: 2021-12-22
    Sponsor Name:Akari Therapeutics Plc
    Full Title: A randomized, part A partial blinded and part B double blinded, placebo-controlled 24-week clinical study to evaluate the efficacy and safety of nomacopan therapy in adult patients with bullous pem...
    Medical condition: moderate to severe bullous pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-000095-17 Sponsor Protocol Number: HOLOGENE17 Start Date*: 2017-08-17
    Sponsor Name:Holostem Terapie Avanzate s.r.l.
    Full Title: PROSPECTIVE, OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED EPIDERMAL GRAFTS CONTAINING EPIDERMAL STEM CELLS GENETICALLY MODIFIED WITH A GAMMA-RETR...
    Medical condition: JEB is genetically and clinically heterogeneous characterized by mutations in COL17A1,encoding for Collagen17 protein. COLXVII is a collagenous transmembrane type II protein component of the hemide...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003542-36 Sponsor Protocol Number: LPS16763 Start Date*: 2021-01-19
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A multi-center, exploratory study to assess dupilumab effect on pruritus neuro-mechanisms in patients with atopic dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000287-32 Sponsor Protocol Number: D325AC00002 Start Date*: 2020-12-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients with Bullous Pemphigoid (FJORD)
    Medical condition: Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended) DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2017-002836-18 Sponsor Protocol Number: AK801 Start Date*: 2018-05-07
    Sponsor Name:Akari Therapeutics Plc.
    Full Title: A Phase IIa open label single arm study of safety and efficacy of rVA576 in adult mild to moderate Bullous Pemphigoid subjects
    Medical condition: Mild to Moderate Bullous Pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002591-40 Sponsor Protocol Number: P180501J Start Date*: 2018-11-26
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Evaluation of bronchial remodeling during mepolizumab treatment in severe eosinophilic asthma
    Medical condition: severe oesinophilic asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10068462 Eosinophilic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003774-27 Sponsor Protocol Number: BC-180-12 Start Date*: 2014-01-20
    Sponsor Name:AlgiPharma AS
    Full Title: An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis pati...
    Medical condition: Cystic fibrosis (CF) is an autosomal, recessive inheritable disease caused by a homozygote defect at the long arm of Chromosome 7. This mutation causes absence or defect of the cystic fibrosis tran...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-000027-14 Sponsor Protocol Number: T-19-11318v19 Start Date*: 2018-08-20
    Sponsor Name:Imperial College London
    Full Title: A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment Chronic Active Antibody Mediated Rejection in Renal Transplantation
    Medical condition: Chronic active antibody mediated rejection of renal transplants
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2016-002181-32 Sponsor Protocol Number: RG012-03 Start Date*: 2016-12-07
    Sponsor Name:Regulus Therapeutics Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Dose Selection, and Preliminary Efficacy of Weekly RG 012 Injections in Pat...
    Medical condition: Alport syndrome is an inherited form of kidney disease caused by mutations in genes coding for the capillary basement membrane collagen IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004394-10 Sponsor Protocol Number: ACT16248 Start Date*: 2020-06-30
    Sponsor Name:Genzyme Corporation
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administe...
    Medical condition: Congenital, hereditary and neonatal diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10001843 Alport's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003682-34 Sponsor Protocol Number: VKTX01 Start Date*: 2019-10-23
    Sponsor Name:Vitaeris Inc.
    Full Title: A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients
    Medical condition: Chronic Active Antibody-Mediated Rejection (CABMR) in Kidney Transplant Recipients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended) BE (Completed) DE (Completed) NL (Completed) AT (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-001377-28 Sponsor Protocol Number: 27577 Start Date*: 2008-06-11
    Sponsor Name:Merck Serono International S.A.
    Full Title: Phase IV, one-day, single blood sampling study to investigate severe thrombocytopenia and autoimmune diseases in psoriasis subjects previously treated with RAPTIVA® (efalizumab) in the framework of...
    Medical condition: Adult patients with moderate to severe chronic plaque psoriasis -- who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosp...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061664 Autoimmune disorder LLT
    9.1 10025139 Lupus erythematosus systemic LLT
    9.1 10047888 Wegener's granulomatosis LLT
    9.1 10002817 Antiphospholipid syndrome LLT
    9.1 10040767 Sjogren's syndrome LLT
    9.1 10039073 Rheumatoid arthritis LLT
    9.1 10028245 Multiple sclerosis LLT
    9.1 10045228 Type I diabetes mellitus LLT
    9.1 10011401 Crohn's disease LLT
    9.1 10009900 Colitis ulcerative LLT
    9.1 10003827 Autoimmune hepatitis LLT
    9.1 10049046 Autoimmune thyroiditis LLT
    9.1 10003822 Autoimmune haemolytic anaemia NOS LLT
    9.1 10034697 Pernicious anemia LLT
    9.1 10028417 Myasthenia gravis LLT
    9.1 10018620 Goodpasture's syndrome LLT
    9.1 10018766 Guillain Barre syndrome LLT
    9.1 10043554 Thrombocytopenia LLT
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006658-24 Sponsor Protocol Number: 8024 Start Date*: 2009-03-05
    Sponsor Name:University of Nottingham
    Full Title: A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid
    Medical condition: BP is a serious condition with a significant associated morbidity and mortality rate. Widespread tense and haemorrhagic blisters, skin erosions and severe itching cause patients a great deal of dis...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006568 Bullous pemphigoid NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001009-98 Sponsor Protocol Number: allo-APZ2-EB-II-01 Start Date*: 2019-03-01
    Sponsor Name:RHEACELL GmbH & Co. KG
    Full Title: An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB)
    Medical condition: Recessive dystrophic epidermolysis bullosa (RDEB)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:10:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA